Bexarotene Amdipharm
Retinoid X receptor agonist for cutaneous T-cell lymphoma (CTCL)
Quick facts about Bexarotene Amdipharm
Key Takeaways
- Specialist-only medication: Bexarotene should only be prescribed and supervised by physicians experienced in the treatment of cutaneous T-cell lymphoma
- Significant lipid effects: Hyperlipidaemia (especially elevated triglycerides) occurs in approximately 70-80% of patients and requires proactive management
- Thyroid monitoring essential: Bexarotene causes central hypothyroidism in most patients, requiring thyroid hormone replacement therapy
- Absolutely contraindicated in pregnancy: Bexarotene is teratogenic; two forms of contraception are mandatory for women of childbearing potential
- Take with food: Capsules must be taken with a meal to enhance absorption and reduce gastrointestinal side effects
What Is Bexarotene Amdipharm and What Is It Used For?
Bexarotene Amdipharm is a synthetic retinoid that selectively activates retinoid X receptors (RXRs) to produce anti-tumour effects. It is used to treat the skin manifestations of advanced cutaneous T-cell lymphoma (CTCL) in adult patients who have not responded adequately to at least one prior systemic treatment.
Cutaneous T-cell lymphoma is a group of rare non-Hodgkin lymphomas characterised by the accumulation of malignant T-lymphocytes in the skin. The most common subtypes are mycosis fungoides and Sézary syndrome. These conditions typically present with persistent patches, plaques, or tumours on the skin, and in advanced stages may involve lymph nodes, blood, and internal organs. CTCL affects approximately 6-10 people per million per year worldwide, with the highest incidence in individuals aged 50-70 years.
Bexarotene belongs to a class of compounds known as rexinoids, which are selective retinoid X receptor agonists. Unlike classical retinoids (such as tretinoin or isotretinoin) that primarily activate retinoic acid receptors (RARs), bexarotene specifically targets RXRs. These nuclear receptors form heterodimers with several other receptor partners, including RARs, thyroid hormone receptors, vitamin D receptors, and peroxisome proliferator-activated receptors (PPARs). By modulating these pathways, bexarotene influences gene expression involved in cellular differentiation, proliferation, apoptosis, and immune regulation.
The clinical development of bexarotene for CTCL was based on pivotal phase II and III clinical trials demonstrating significant overall response rates of approximately 45-55% in patients with refractory or persistent early-stage disease and approximately 45% in advanced-stage disease. The European Medicines Agency (EMA) granted marketing authorisation for bexarotene oral capsules, and it remains an important treatment option within the therapeutic armamentarium for CTCL as recommended by the European Organisation for Research and Treatment of Cancer (EORTC), the International Society for Cutaneous Lymphomas (ISCL), and the National Comprehensive Cancer Network (NCCN).
Bexarotene is not a cytotoxic chemotherapy agent. It works through receptor-mediated gene regulation rather than direct DNA damage. This mechanism of action means its side effect profile differs significantly from traditional chemotherapy, though it does cause characteristic metabolic effects that require careful monitoring.
How Bexarotene Works
Bexarotene exerts its therapeutic effect by binding to and activating retinoid X receptors (RXR-alpha, RXR-beta, and RXR-gamma). Once activated, RXRs function as ligand-dependent transcription factors that regulate the expression of genes involved in several critical cellular processes. The anti-tumour activity of bexarotene in CTCL is thought to result from multiple mechanisms, including induction of apoptosis (programmed cell death) in malignant T-cells, inhibition of cell proliferation, modulation of immune function, and promotion of cellular differentiation.
The pharmacokinetics of bexarotene are characterised by absorption that is significantly enhanced when taken with food, particularly a fat-containing meal. Peak plasma concentrations are typically reached within approximately 2 hours after oral administration. Bexarotene is highly protein-bound (greater than 99%) and is extensively metabolised by the cytochrome P450 3A4 (CYP3A4) enzyme system. The terminal elimination half-life is approximately 7 hours, supporting once-daily dosing.
What Should You Know Before Taking Bexarotene Amdipharm?
Before starting bexarotene, your doctor must evaluate your lipid levels, thyroid function, liver function, and blood counts. Bexarotene is absolutely contraindicated in pregnancy and requires strict contraception measures. Several important drug interactions must be considered.
Contraindications
Bexarotene must not be used in the following situations:
- Pregnancy: Bexarotene is teratogenic (causes birth defects) and is absolutely contraindicated during pregnancy. Women must have a confirmed negative pregnancy test within one week before starting treatment
- Breastfeeding: It is not known whether bexarotene is excreted in human milk. Due to the potential for serious adverse effects in nursing infants, breastfeeding must be discontinued
- Hypersensitivity: Known allergy to bexarotene or any of the excipients in the capsule formulation
- Uncontrolled hyperlipidaemia: Patients with severely elevated baseline triglycerides or cholesterol that cannot be adequately controlled
- Uncontrolled thyroid disease: Active, untreated thyroid conditions
- Hepatic insufficiency: Severe liver disease
- Active systemic infection: Ongoing, uncontrolled systemic infections
- Hypervitaminosis A: Concurrent excess vitamin A
- Concomitant use with gemfibrozil: Gemfibrozil significantly increases bexarotene plasma levels and is contraindicated
Warnings and Precautions
Treatment with bexarotene requires close clinical and laboratory monitoring. Several important warnings apply to patients considering or currently receiving this medication:
Lipid abnormalities: Bexarotene causes major dose-dependent increases in fasting triglycerides and total cholesterol in the majority of patients. Triglyceride levels can increase by 2-5 times baseline, and in some cases dramatically higher. These elevations occur rapidly, typically within the first 2-4 weeks of therapy. Untreated severe hypertriglyceridaemia can lead to acute pancreatitis, a potentially life-threatening condition. Fasting lipid levels should be monitored before treatment, weekly during the first month, and then at regular intervals. Concomitant lipid-lowering therapy (typically with atorvastatin or fenofibrate, but not gemfibrozil) is often required.
Thyroid function: Bexarotene induces reversible biochemical central hypothyroidism in approximately 30-60% of patients through suppression of thyroid-stimulating hormone (TSH). This occurs independently of the dose. Thyroid function tests (TSH, free T4) should be obtained at baseline and monitored regularly. Many patients will require levothyroxine supplementation during treatment. Thyroid function typically normalises after discontinuation of bexarotene.
Hepatotoxicity: Elevations in liver function tests (particularly transaminases) have been observed. Liver function should be monitored at baseline, after the first month, and periodically thereafter. Dose reduction or discontinuation may be necessary if significant hepatic enzyme elevation occurs.
Leucopenia and neutropenia: Bexarotene can suppress white blood cell counts. Complete blood counts should be monitored at baseline and throughout treatment. Patients should report signs of infection promptly.
Cataracts: A higher incidence of cataracts has been reported in patients receiving bexarotene compared to the general population. Ophthalmological examination is recommended before starting treatment and if visual symptoms develop.
Bexarotene is a known teratogen. Women of childbearing potential must use two reliable forms of contraception simultaneously, beginning one month before initiating therapy, throughout treatment, and for at least one month after the last dose. Note that bexarotene can reduce the effectiveness of hormonal contraceptives, so at least one non-hormonal method of contraception must be used. Monthly pregnancy tests are recommended during treatment.
Pregnancy and Breastfeeding
Bexarotene is classified as a known teratogen based on its mechanism of action and animal studies demonstrating fetal harm. Retinoids as a class are well-established teratogens, and bexarotene carries significant risk of causing birth defects including craniofacial, cardiac, thymic, and central nervous system malformations. The drug must not be used during pregnancy under any circumstances.
Women of childbearing potential must meet all of the following criteria before starting bexarotene: a negative serum pregnancy test within one week before the first dose, commitment to using two simultaneous forms of effective contraception (including at least one non-hormonal method since bexarotene can reduce hormonal contraceptive efficacy), and understanding of the teratogenic risk through appropriate counselling. Monthly pregnancy testing during treatment is strongly recommended.
It is unknown whether bexarotene is excreted in human breast milk. Given the potential for serious adverse reactions in breastfed infants, women must discontinue breastfeeding before starting bexarotene and must not breastfeed during treatment or for at least one month after the final dose.
Men taking bexarotene who have partners of childbearing potential should also be counselled regarding the potential reproductive risks, although direct evidence of male-mediated teratogenicity in humans is limited. The use of condoms during sexual intercourse is recommended as a precautionary measure.
How Does Bexarotene Amdipharm Interact with Other Drugs?
Bexarotene is primarily metabolised by CYP3A4 and also induces CYP3A4 activity. This creates the potential for clinically significant interactions with many commonly used medications, including lipid-lowering agents, hormonal contraceptives, and various drugs metabolised by the CYP3A4 pathway.
Drug interactions are a critical consideration when prescribing bexarotene. Because bexarotene is both a substrate and an inducer of cytochrome P450 3A4 (CYP3A4), it can affect and be affected by many other medications. Additionally, bexarotene's characteristic metabolic effects (hyperlipidaemia, hypothyroidism) can compound the effects of or interfere with concomitant medications. All patients should inform their prescribing physician about every medication, supplement, and herbal product they are taking before starting bexarotene.
Major Interactions
| Drug/Class | Interaction | Clinical Significance | Recommendation |
|---|---|---|---|
| Gemfibrozil | Substantially increases bexarotene plasma concentrations | Increased toxicity risk; potential for severe hyperlipidaemia | Contraindicated — do not co-administer |
| CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin, grapefruit juice) | May increase bexarotene plasma levels | Increased risk of adverse effects | Use with caution; monitor for toxicity |
| CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, phenobarbital, St. John's Wort) | May decrease bexarotene plasma levels | Reduced therapeutic efficacy | Avoid if possible; consider dose adjustment |
| Hormonal contraceptives | Bexarotene induces CYP3A4, reducing contraceptive effectiveness | Contraceptive failure; pregnancy risk | Must use additional non-hormonal contraception |
| Vitamin A supplements | Additive retinoid toxicity | Increased risk of hypervitaminosis A symptoms | Limit vitamin A intake to ≤15,000 IU/day |
Minor Interactions
| Drug/Class | Interaction | Recommendation |
|---|---|---|
| Insulin / oral hypoglycaemics | Bexarotene may enhance insulin sensitivity; risk of hypoglycaemia in diabetic patients | Monitor blood glucose closely; adjust diabetes therapy as needed |
| Tamoxifen | Both agents may affect lipid metabolism | Monitor lipid levels more frequently |
| Dexamethasone | CYP3A4 inducer; may reduce bexarotene levels | Monitor treatment response; consider dose adjustment |
| Atorvastatin / other statins | Commonly co-prescribed for bexarotene-induced hyperlipidaemia; potential for increased myopathy risk | Monitor creatine kinase (CK) and muscle symptoms |
| Levothyroxine | Often required to treat bexarotene-induced hypothyroidism; bexarotene may alter thyroid hormone metabolism | Monitor TSH and adjust levothyroxine dose accordingly |
What Is the Correct Dosage of Bexarotene Amdipharm?
The recommended starting dose of oral bexarotene is 300 mg/m²/day, taken as a single dose with a meal. The dose is calculated based on body surface area and rounded to the nearest 75 mg increment. Dose adjustments are made based on tumour response and tolerability.
Bexarotene dosing is individualised based on body surface area (BSA). The capsules should always be taken with food, preferably with a fat-containing meal, as this significantly improves absorption. The total daily dose is taken as a single dose. Below are detailed dosing guidelines for different patient populations and scenarios.
Adults
Standard Adult Dosing
Starting dose: 300 mg/m²/day taken orally as a single daily dose with a meal.
Dose calculation example: For a patient with a BSA of 1.8 m²: 300 × 1.8 = 540 mg/day, rounded to 525 mg (7 capsules of 75 mg).
Dose escalation: If no adequate tumour response is observed after 8 weeks of treatment at 300 mg/m²/day and the medication is well tolerated, the dose may be increased to 400 mg/m²/day with careful monitoring.
Dose reduction: If significant toxicity develops, the dose may be reduced to 200 mg/m²/day. If toxicity persists at the reduced dose, treatment should be temporarily interrupted or permanently discontinued.
| BSA (m²) | 300 mg/m²/day | Number of 75 mg Capsules | 400 mg/m²/day | Number of 75 mg Capsules |
|---|---|---|---|---|
| 1.50 | 450 mg | 6 | 600 mg | 8 |
| 1.65 | 495 mg | 7 | 660 mg | 9 |
| 1.80 | 540 mg | 7 | 720 mg | 10 |
| 1.95 | 585 mg | 8 | 780 mg | 10 |
| 2.10 | 630 mg | 8 | 840 mg | 11 |
Children
Bexarotene has not been studied in paediatric patients. The safety and efficacy of bexarotene in children and adolescents under 18 years of age have not been established. CTCL is extremely rare in the paediatric population. Bexarotene should not be used in children unless under exceptional circumstances and with specialist guidance from a paediatric oncologist or dermatologist experienced in cutaneous lymphomas.
Elderly
No specific dose adjustment is required based on age alone. However, elderly patients may have reduced hepatic and renal function and are more likely to have comorbidities and concurrent medications that could influence bexarotene metabolism or increase susceptibility to adverse effects. Careful monitoring of lipid levels, thyroid function, liver function, and haematological parameters is particularly important in this population. Starting at the lower end of the dosing range and escalating cautiously may be prudent in elderly patients with significant comorbidities.
Missed Dose
If a dose of bexarotene is missed, patients should take the missed dose as soon as they remember, provided it is still on the same day and taken with food. If the missed dose is not remembered until the next day, patients should skip the missed dose entirely and resume the regular dosing schedule. A double dose should never be taken to make up for a missed dose, as this increases the risk of dose-dependent toxicity including severe hyperlipidaemia.
Overdose
There is limited clinical experience with bexarotene overdose. In the event of an overdose, symptoms are expected to be extensions of the known adverse effects, particularly severe hyperlipidaemia, headache, and general malaise. There is no specific antidote for bexarotene. Management should be supportive and symptomatic, with particular attention to monitoring and managing lipid levels and preventing pancreatitis. Contact your local poison control centre or emergency services immediately if overdose is suspected.
What Are the Side Effects of Bexarotene Amdipharm?
The most characteristic side effects of bexarotene are metabolic: hyperlipidaemia (especially hypertriglyceridaemia) occurs in the majority of patients and central hypothyroidism is also very common. Other frequent side effects include headache, leucopenia, skin rash, and fatigue. Most metabolic side effects are reversible after discontinuation.
Like all medicines, bexarotene can cause side effects, although not everybody gets them. The side effect profile of bexarotene is dominated by predictable, dose-dependent metabolic effects that can be managed with appropriate monitoring and supportive therapy. Understanding these effects is crucial for safe treatment. If you experience any side effects, including those not listed here, talk to your doctor or pharmacist.
Very Common (affects more than 1 in 10 patients)
- Hyperlipidaemia — elevated blood triglycerides and cholesterol (70-80% of patients)
- Hypothyroidism — underactive thyroid due to TSH suppression (30-60%)
- Leucopenia — reduced white blood cell count
- Headache
- Asthenia — fatigue and weakness
- Skin rash — including exfoliative dermatitis
- Hypercholesterolaemia — elevated total cholesterol
Common (affects 1 to 10 in 100 patients)
- Anaemia — reduced red blood cell count
- Peripheral oedema — swelling, particularly in legs and ankles
- Dry skin — xerosis
- Alopecia — hair thinning or loss
- Nausea and diarrhoea
- Elevated liver enzymes (transaminases)
- Pruritus — itching
- Abdominal pain
- Insomnia
- Dizziness
Uncommon (affects 1 to 10 in 1,000 patients)
- Pancreatitis — inflammation of the pancreas (usually secondary to severe hypertriglyceridaemia)
- Cataracts — lens opacity
- Allergic reactions
- Photosensitivity — increased sensitivity to sunlight
- Decreased visual acuity
Rare (affects fewer than 1 in 1,000 patients)
- Severe hepatotoxicity — serious liver damage
- Severe hypersensitivity reactions
- Rhabdomyolysis (particularly when combined with statins)
Contact your doctor or go to the nearest emergency department immediately if you experience: severe abdominal pain (possible pancreatitis), unexplained muscle pain or weakness (possible rhabdomyolysis), yellowing of the skin or eyes (possible liver damage), signs of severe allergic reaction (difficulty breathing, swelling of face/throat), or severe skin reactions. Do not wait for your next scheduled appointment.
Most of the metabolic side effects of bexarotene, particularly hyperlipidaemia and hypothyroidism, are reversible and typically resolve within weeks to months after discontinuation of therapy. Proactive management with lipid-lowering agents and thyroid hormone replacement can allow patients to continue treatment while minimising the impact of these effects. Regular blood monitoring is the cornerstone of safe bexarotene therapy and enables early detection and intervention for all significant adverse effects.
Patients should also be aware that bexarotene can decrease the effectiveness of hormonal contraceptives and may affect blood glucose levels. Any new symptoms or changes in existing conditions should be promptly reported to the treating physician, even if they seem unrelated to the medication.
How Should You Store Bexarotene Amdipharm?
Store bexarotene capsules below 25°C in the original packaging to protect from light. Keep out of reach and sight of children. Do not use after the expiry date printed on the carton and blister.
Proper storage of bexarotene capsules is important to maintain the medication's stability and effectiveness throughout its shelf life. The soft capsules should be stored at temperatures not exceeding 25°C (77°F). They should be kept in their original packaging (carton and blister pack) to protect them from light exposure, which can degrade the active substance.
Do not store bexarotene capsules in the bathroom or near a kitchen sink, as moisture and heat from these environments can compromise the integrity of the soft gelatin capsules. Avoid freezing the capsules, as extreme cold can alter their physical properties and potentially affect drug release characteristics.
As with all medicines, keep bexarotene out of the reach and sight of children. Given that bexarotene is a teratogenic medication, particular care should be taken to ensure that it is stored securely and that capsules are not accessible to anyone other than the intended patient. Any unused medication or medication that has passed its expiry date should be returned to a pharmacy for safe disposal rather than discarded in household waste or flushed down the toilet.
What Does Bexarotene Amdipharm Contain?
Each Bexarotene Amdipharm soft capsule contains 75 mg of bexarotene as the active substance, along with inactive excipients necessary for the capsule formulation.
The active substance in Bexarotene Amdipharm is bexarotene. Each soft capsule contains 75 mg of bexarotene. The chemical name of bexarotene is 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic acid. It is a white to off-white powder that is practically insoluble in water but soluble in organic solvents.
The soft capsule formulation contains several inactive excipients (non-active ingredients) that serve important pharmaceutical functions:
- Macrogol (polyethylene glycol) — serves as a solvent for the active ingredient within the capsule fill
- Polysorbate 20 — an emulsifier that helps maintain uniform drug distribution
- Povidone — aids in drug dissolution and absorption
- Butylated hydroxyanisole (BHA) — an antioxidant that prevents degradation of bexarotene
The capsule shell itself is composed of gelatin, glycerol (as a plasticiser), sorbitol special (as a plasticiser), and titanium dioxide (as an opacifying agent). The printing ink on the capsule contains pharmaceutical grade ink components.
Patients with known allergies or intolerances to any of these excipients should inform their prescribing physician before starting bexarotene therapy. In particular, patients with sorbitol intolerance should be aware that the capsule shell contains sorbitol.
Frequently Asked Questions About Bexarotene Amdipharm
Bexarotene (Bexarotene Amdipharm) is used to treat cutaneous T-cell lymphoma (CTCL), a type of non-Hodgkin lymphoma that primarily affects the skin. It is specifically indicated for patients whose disease has not responded adequately to at least one prior systemic treatment. CTCL includes conditions such as mycosis fungoides and Sézary syndrome. Bexarotene works by activating retinoid X receptors to slow cancer cell growth and promote cell death.
The most common side effects are metabolic in nature. Hyperlipidaemia (elevated blood fats, particularly triglycerides and cholesterol) occurs in approximately 70-80% of patients and is the most characteristic effect. Hypothyroidism (underactive thyroid) affects 30-60% of patients. Other common side effects include headache, leucopenia (low white blood cell count), skin rash, and fatigue. Most metabolic side effects are reversible after stopping the medication.
No, absolutely not. Bexarotene is a known teratogen, meaning it can cause serious birth defects. It is completely contraindicated during pregnancy. Women of childbearing potential must use two reliable forms of contraception simultaneously (including at least one non-hormonal method, since bexarotene can reduce the effectiveness of hormonal contraceptives). Contraception must begin one month before treatment, continue throughout, and last at least one month after stopping bexarotene. A negative pregnancy test is required before starting therapy.
Bexarotene is a synthetic retinoid that selectively activates retinoid X receptors (RXRs). These are nuclear transcription factors that regulate gene expression involved in cell growth, differentiation, and programmed cell death (apoptosis). When bexarotene binds to RXRs, it modulates the activity of genes that control how cells grow and divide, ultimately slowing the growth of malignant T-cells in the skin and promoting their destruction. Unlike traditional chemotherapy, it does not directly damage DNA.
Regular blood monitoring is essential during bexarotene therapy. Required tests include: fasting lipid panel (triglycerides and cholesterol) — weekly for the first 2-4 weeks, then at regular intervals; thyroid function tests (TSH and free T4); liver function tests (transaminases, bilirubin); complete blood count with differential; and fasting blood glucose. Baseline tests should be performed before starting treatment. Your physician will determine the exact monitoring schedule based on your individual risk factors and treatment response.
Yes, bexarotene should always be taken with food, specifically with a meal. Absorption of bexarotene is significantly enhanced when taken with a fat-containing meal compared to taking it on an empty stomach. Taking the capsules with food also helps reduce gastrointestinal side effects such as nausea. The total daily dose should be taken as a single dose with a main meal.
References
- European Medicines Agency (EMA). Targretin (bexarotene) — Summary of Product Characteristics. EMA/CHMP. Available at: www.ema.europa.eu.
- Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. Journal of Clinical Oncology. 2001;19(9):2456-2471.
- Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology. 2001;137(5):581-593.
- Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2018;29(Suppl 4):iv30-iv40.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Primary Cutaneous Lymphomas. Version 1.2025.
- Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome — Update 2023. European Journal of Cancer. 2023;195:113343.
- Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome. Journal of Clinical Oncology. 2015;33(32):3766-3773.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd List, 2023.
- British National Formulary (BNF). Bexarotene monograph. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk.
- U.S. Food and Drug Administration (FDA). Targretin (bexarotene) capsules prescribing information. FDA Label.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, which includes specialists in clinical pharmacology, oncology, and dermatology with documented expertise in cutaneous lymphoma management.
Written by licensed physicians with expertise in pharmacology and haematological malignancies, following EMA, FDA, and NCCN guidelines for cutaneous T-cell lymphoma.
Independently reviewed by the iMedic Medical Review Board to ensure clinical accuracy, completeness, and adherence to the GRADE evidence framework.
All medical claims are based on peer-reviewed literature, regulatory agency documents (EMA SmPC, FDA label), and international clinical guidelines (NCCN, EORTC, ESMO). Evidence level: 1A.
iMedic receives no pharmaceutical industry funding. All content is editorially independent with no conflicts of interest.